Proteasome inhibitors evoke latent tumor suppression programs in Pro-B MLL Leukemias through MLL-AF4

Cancer Cell

Volumn 25, Issue 4, 2014, Pages 530-542

  Liu, Han ^a,b   Westergard, Todd D ^c   Cashen, Amanda ^c   Piwnica Worms, David R ^d   Kunkle, Lori ^e   Vij, Ravi ^c   Pham, Can G ^a   DiPersio, John ^c   Cheng, Emily H ^a,f   Hsieh, James J ^a,f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PHARMACYCLICS INC   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CASPASE 8; HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MLL AF4 PROTEIN; PROTEASOME; PROTEIN BID; PROTEIN P27; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TURNOVER TIME; UPREGULATION;

ADULT; ANIMALS; APOPTOSIS; BORONIC ACIDS; DNA-BINDING PROTEINS; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MICE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEASOME INHIBITORS; PYRAZINES; RNA, SMALL INTERFERING; TRANSFECTION; TRANSLOCATION, GENETIC;

EID: 84898467113     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.03.008     Document Type: Article

References (62)

1. Adams J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 2004, 4:349-360.
2. Ayton P.M., Cleary M.L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001, 20:5695-5707.
3. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
4. Bhojwani D., Howard S.C., Pui C.H. High-risk childhood acute lymphoblastic leukemia. Clin. Lymphoma Myeloma 2009, 9(Suppl 3):S222-S230.
5. Busslinger M. Transcriptional control of early B cell development. Annu. Rev. Immunol. 2004, 22:55-79.
6. Caslini C., Shilatifard A., Yang L., Hess J.L. The amino terminus of the mixed lineage leukemia protein (MLL) promotes cell cycle arrest and monocytic differentiation. Proc. Natl. Acad. Sci. USA 2000, 97:2797-2802.
7. Chen Y.N., Sharma S.K., Ramsey T.M., Jiang L., Martin M.S., Baker K., Adams P.D., Bair K.W., Kaelin W.G. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. USA 1999, 96:4325-4329.
8. Cheng E.H., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T., Korsmeyer S.J. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 2001, 8:705-711.
9. Chu I.M., Hengst L., Slingerland J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 2008, 8:253-267.
10. Cvek B., Dvorak Z. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. Curr. Pharm. Des. 2011, 17:1483-1499.
11. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
12. Davids M.S., Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J.Clin. Oncol. 2012, 30:3127-3135.
13. Demo S.D., Kirk C.J., Aujay M.A., Buchholz T.J., Dajee M., Ho M.N., Jiang J., Laidig G.J., Lewis E.R., Parlati F., et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007, 67:6383-6391.
14. Dou Y., Milne T.A., Ruthenburg A.J., Lee S., Lee J.W., Verdine G.L., Allis C.D., Roeder R.G. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat. Struct. Mol. Biol. 2006, 13:713-719.
15. Drexler H.G., Quentmeier H., MacLeod R.A. Malignant hematopoietic cell lines: invitro models for the study of MLL gene alterations. Leukemia 2004, 18:227-232.
16. Egle A., Harris A.W., Bouillet P., Cory S. Bim is a suppressor ofMyc-induced mouse B cell leukemia. Proc. Natl. Acad. Sci. USA 2004, 101:6164-6169.
17. Fennell D.A., Chacko A., Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 2008, 27:1189-1197.
18. Garcia-Calvo M., Peterson E.P., Leiting B., Ruel R., Nicholson D.W., Thornberry N.A. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J.Biol. Chem. 1998, 273:32608-32613.
19. Gonzalvez F., Lawrence D., Yang B., Yee S., Pitti R., Marsters S., Pham V.C., Stephan J.P., Lill J., Ashkenazi A. TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol. Cell 2012, 48:888-899.
20. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
21. Hemann M.T., Zilfou J.T., Zhao Z., Burgess D.J., Hannon G.J., Lowe S.W. Suppression of tumorigenesis by the p53 target PUMA. Proc. Natl. Acad. Sci. USA 2004, 101:9333-9338.
22. Hemann M.T., Bric A., Teruya-Feldstein J., Herbst A., Nilsson J.A., Cordon-Cardo C., Cleveland J.L., Tansey W.P., Lowe S.W. Evasion ofthe p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005, 436:807-811.
23. Hideshima T., Ikeda H., Chauhan D., Okawa Y., Raje N., Podar K., Mitsiades C., Munshi N.C., Richardson P.G., Carrasco R.D., Anderson K.C. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114:1046-1052.
24. Hsieh J.J., Cheng E.H., Korsmeyer S.J. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell 2003, 115:293-303.
25. Karnik S.K., Hughes C.M., Gu X., Rozenblatt-Rosen O., McLean G.W., Xiong Y., Meyerson M., Kim S.K. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc. Natl. Acad. Sci. USA 2005, 102:14659-14664.
26. Kim H., Rafiuddin-Shah M., Tu H.C., Jeffers J.R., Zambetti G.P., Hsieh J.J., Cheng E.H. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 2006, 8:1348-1358.
27. Kim H., Tu H.C., Ren D., Takeuchi O., Jeffers J.R., Zambetti G.P., Hsieh J.J., Cheng E.H. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell 2009, 36:487-499.
28. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7:823-833.
29. Liedtke M., Cleary M.L. Therapeutic targeting of MLL. Blood 2009, 113:6061-6068.
30. Liu H., Cheng E.H., Hsieh J.J. Bimodal degradation of MLL bySCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev. 2007, 21:2385-2398.
31. Liu H., Cheng E.H., Hsieh J.J. MLL fusions: pathways to leukemia. Cancer Biol. Ther. 2009, 8:1204-1211.
32. Liu H., Takeda S., Kumar R., Westergard T.D., Brown E.J., Pandita T.K., Cheng E.H., Hsieh J.J. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 2010, 467:343-346.
33. Lowe S.W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004, 432:307-315.
34. Luker G.D., Pica C.M., Song J., Luker K.E., Piwnica-Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat. Med. 2003, 9:969-973.
35. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
36. Mendoza N., Fong S., Marsters J., Koeppen H., Schwall R., Wickramasinghe D. Selective cyclin-dependent kinase 2/cyclin Aantagonists that differ from ATP site inhibitors block tumor growth. Cancer Res. 2003, 63:1020-1024.
37. Milne T.A., Briggs S.D., Brock H.W., Martin M.E., Gibbs D., Allis C.D., Hess J.L. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol. Cell 2002, 10:1107-1117.
38. Milne T.A., Hughes C.M., Lloyd R., Yang Z., Rozenblatt-Rosen O., Dou Y., Schnepp R.W., Krankel C., Livolsi V.A., Gibbs D., et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102:749-754.
39. Mohan M., Lin C., Guest E., Shilatifard A. Licensed to elongate: amolecular mechanism for MLL-based leukaemogenesis. Nat. Rev. Cancer 2010, 10:721-728.
40. Muntean A.G., Hess J.L. The pathogenesis of mixed-lineage leukemia. Annu. Rev. Pathol. 2012, 7:283-301.
41. Murphy D.J., Junttila M.R., Pouyet L., Karnezis A., Shchors K., Bui D.A., Brown-Swigart L., Johnson L., Evan G.I. Distinct thresholds govern Myc's biological output invivo. Cancer Cell 2008, 14:447-457.
42. Muzio M., Chinnaiyan A.M., Kischkel F.C., O'Rourke K., Shevchenko A., Ni J., Scaffidi C., Bretz J.D., Zhang M., Gentz R., et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85:817-827.
43. Oyama T., Sasagawa S., Takeda S., Hess R.A., Lieberman P.M., Cheng E.H., Hsieh J.J. Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs. Dev. Cell 2013, 27:188-200.
44. Pelengaris S., Khan M., Evan G.I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002, 109:321-334.
45. Perciavalle R.M., Opferman J.T. Delving deeper: MCL-1's contributions to normal and cancer biology. Trends Cell Biol. 2013, 23:22-29.
46. Ren D., Tu H.C., Kim H., Wang G.X., Bean G.R., Takeuchi O., Jeffers J.R., Zambetti G.P., Hsieh J.J., Cheng E.H. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 2010, 330:1390-1393.
47. Sarkisian C.J., Keister B.A., Stairs D.B., Boxer R.B., Moody S.E., Chodosh L.A. Dose-dependent oncogene-induced senescence invivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 2007, 9:493-505.
48. Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007, 21:3214-3231.
49. Smith M.C., Luker K.E., Garbow J.R., Prior J.L., Jackson E., Piwnica-Worms D., Luker G.D. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004, 64:8604-8612.
50. Takeda S., Chen D.Y., Westergard T.D., Fisher J.K., Rubens J.A., Sasagawa S., Kan J.T., Korsmeyer S.J., Cheng E.H., Hsieh J.J. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev. 2006, 20:2397-2409.
51. Takeda S., Liu H., Sasagawa S., Dong Y., Trainor P.A., Cheng E.H., Hsieh J.J. HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. J.Clin. Invest. 2013, 123:3154-3165.
52. Thiel A.T., Blessington P., Zou T., Feather D., Wu X., Yan J., Zhang H., Liu Z., Ernst P., Koretzky G.A., Hua X. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 2010, 17:148-159.
53. Thomas M., Gessner A., Vornlocher H.P., Hadwiger P., Greil J., Heidenreich O. Targeting MLL-AF4 with short interfering RNAs inhibits clonogenicity and engraftment of t(4;11)-positive human leukemic cells. Blood 2005, 106:3559-3566.
54. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., Johnson E.F., Marsh K.C., Mitten M.J., Nimmer P., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428.
55. Walensky L.D. From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J.Clin. Oncol. 2012, 30:554-557.
56. Wang Z., Smith K.S., Murphy M., Piloto O., Somervaille T.C., Cleary M.L. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008, 455:1205-1209.
57. Wang J., Muntean A.G., Hess J.L. ECSASB2 mediates MLL degradation during hematopoietic differentiation. Blood 2012, 119:1151-1161.
58. Xia Z.B., Popovic R., Chen J., Theisler C., Stuart T., Santillan D.A., Erfurth F., Diaz M.O., Zeleznik-Le N.J. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc. Natl. Acad. Sci. USA 2005, 102:14028-14033.
59. Yip B.H., So C.W. Mixed lineage leukemia protein in normal and leukemic stem cells. Exp. Biol. Med. (Maywood) 2013, 238:315-323.
60. Yokoyama A., Somervaille T.C., Smith K.S., Rozenblatt-Rosen O., Meyerson M., Cleary M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005, 123:207-218.
61. Yokoyama A., Lin M., Naresh A., Kitabayashi I., Cleary M.L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010, 17:198-212.
62. Zhang J., Seet C.S., Sun C., Li J., You D., Volk A., Breslin P., Li X., Wei W., Qian Z., et al. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia. Mol. Oncol. 2013, 7:1069-1082.